Navigation Links
AltheaDx Incorporates Next-Generation Sequencing Into Its Clinical Testing Pipeline.

SAN DIEGO, June 27, 2011 /PRNewswire/ -- AltheaDx, Inc. today announced the launch of next-generation sequencing "NGS" services into its clinical molecular pathology lab for application in biomarker discovery and clinical trial testing.  AltheaDx intends to utilize NGS for both monitoring known and discovering new complex genetic changes that underlie different cancer types.  

"The addition of NGS greatly expands our OncoScore™ initiative and adds to our core competency in quantitative PCR.  NGS now enables us to monitor the complex genomic changes indicative of certain cancer subtypes and their impact on therapeutic activity at a speed, cost and sensitivity that is only now achievable with the new systems coming on the market," said Francois Ferre, Ph.D., Co-founder and CEO of AltheaDx.  

Dr. Ferre further commented that "we fully expect that the new NGS systems will be highly synergistic to our directed strategy of creating cancer-specific molecular subtype panels in partnership with Compendia Bioscience.  The utilization of NGS systems is also highly complementary to our RT-PCR-based gene expression panels, allowing us to capture the full breadth of genetic activity in cancer.  Our adoption and implementation of these new technologies, be it PCR, microarray or NGS, fits perfectly with our pharma-focused testing services and the demand for cutting edge strategies for genetic analysis."

AltheaDx's CSO, Dr. Joseph Monforte, noted that "we plan to take the lead in providing the pharmaceutical and biotechnology industry with well-characterized, predictive biomarker panels composed of both genetic polymorphisms and gene expression patterns.  Our combined OncoScore™ RNA and DNA panels will provide a detailed characterization of the key molecular variables that comprise the unique genetics of each patient.  It is only with this level of characterization that we will be able to identify the main factors driving therapeutic sensitivity and resistance in clinical trials."

AltheaDx has a decade-long history in preclinical and clinical assay development and testing.  With the latest PCR, microarray and sequencing platforms AltheaDx is able provide pharmaceutical and biotechnology partners with both predefined and customized solutions for characterizing preclinical models and clinical patients at a high level of resolution on both the RNA and DNA front.  

About AltheaDx, Inc.

AltheaDx, a leading diagnostic development and testing company, with San Diego-based GLP & CLIA certified laboratories, provides clinical biomarker discovery, assay development and validation services that support researchers worldwide in their efforts to utilize genomic information for the advancement of novel therapies.  AltheaDx plays a critical role in helping pharma to discover and validate biomarkers that can predict drug response, and then to provide an efficient seamless commercialization path to bring the tests to market.  The goal of AltheaDx is to reduce the time, risk, and cost of therapeutic development for pharma partners.  For more information on how we are making a difference, please visit our website: For more information on how we are making a difference, please visit our website:  Follow AltheaDx on Twitter:  @AltheaDx

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to applying the global collection of cancer genomic data to impact patient treatment by enabling the discovery and development of better cancer diagnostics and treatments.

For additional information please contact:
AltheaDx:  Steve Daniel,
Compendia Bioscience:  John Freshley,

SOURCE AltheaDx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panelâ„¢
2. Prolifiq Announces Software for Life Sciences: Accelerates Sales, Embeds Adherence to Regulatory Compliance, Incorporates Good Promotional Practices
3. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
4. Isilon IQ Powers Data Storage for Next-Generation DNA Sequencing
5. Capture of nanomagnetic fingerprints a boost for next-generation information storage media
6. Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine
7. Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi
8. Cell Biosciences Launches Next-Generation Protein Characterization System
9. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
10. SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
11. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/26/2015)... Calif. , Oct. 26, 2015  Delta ID ... biometric authentication to mobile and PC devices, announced its ... smartphone, the arrows NX F-02H launched by NTT DOCOMO, ... NX F-02H is the second smartphone to include iris ... technology in ARROWS NX F-04G in May 2015, world,s ...
(Date:10/23/2015)... BERLIN and GOLETA, California ... the HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce ... and eye tracking data captured during interactive real-world tasks ... plug and play integration of their established wearable solutions ... researchers to synchronize gaze behavior captured with SMI ...
Breaking Biology News(10 mins):